ReviewExperimental biology and medicine (Maywood, N.J.)2022
Sickle cell disease as an accelerated aging syndrome.
Review in Experimental biology and medicine (Maywood, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Methylation profile of individuals with sickle cell trait.Epigenetics · 2025Pooled it
- Quantifying dilated perivascular spaces in children with sickle cell disease.Pediatric blood & cancer · 2024Trial
- Variations in mitochondrial genome as potential prognostic markers in sickle cell disease.Haematologica · 2026Article
- Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.Seminars in hematology · 2026Article
- Global Prevalence of Alloimmunization in Adults with Sickle Cell Disease Receiving Red Blood Cell Transfusions: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Frailty phenotype in adults with sickle cell disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Chronic pain in the aging adult with sickle cell disease.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- When Blood Disorders Meet Cancer: Uncovering the Oncogenic Landscape of Sickle Cell Disease.Journal of clinical medicine · 2025Review
- Sickle Cell Diastolic Cardiomyopathy and Mortality Risk: A Novel Echocardiographic Framework for Prognostic Stratification.American journal of hematology · 2025Article
- Risk factors associated with pain episodes among sickle cell patients that visited Mulago National Referral Hospital-Uganda.BMC health services research · 2025Article
- Article
- "I can't let it stop me": perspectives on aging from older adults with sickle cell disease.Journal of sickle cell disease · 2025Article
- Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16Aging · 2024Article
- Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease.Journal of the American Heart Association · 2024Observational
- Article
- Lysophosphatidic Acid Receptor 3 Activation Is Involved in the Regulation of Ferroptosis.International journal of molecular sciences · 2024Article
- Characterizing epigenetic aging in an adult sickle cell disease cohort.Blood advances · 2024Article
- Telomere Dynamics in Sickle Cell Anemia: Unraveling Molecular Aging and Disease Progression.Journal of blood medicine · 2024Review
- The indignities of shielding during the COVID-19 pandemic for people with sickle cell disorders: an interpretative phenomenological analysis.Frontiers in sociology · 2024Article
- White-matter abnormalities and cognitive dysfunction are linked to astrocyte activation in sickle mice.PNAS nexus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Sickle cell disease (SCD) is characterized by vaso-occlusion, hemolysis, and systemic manifestations that form the hallmark of the disease. Apart from morbidity, SCD is also associated with increased mortality and decreased quality of life. Aging is a natural phenomenon that is associated with changes at cellular, tissue, and organ levels, in addition to the loss of physical fitness, increased susceptibility to diseases, and a higher likelihood of mortality. Some of the cellular mechanisms involved in normal (or physiological) aging include abnormalities of sphingolipids (ceramides) and reduced length of the telomere. These changes have also been documented in SCD. Cellular, organs, and physical manifestations of SCD resemble an accelerated aging syndrome. Sickle erythrocytes also acquire morphological features similar to that of aged normal erythrocytes and are thus picked up early by the macrophages for destruction. Brain, kidney, heart, innate and adaptive immune system, and musculoskeletal system of patients with SCD exhibit morphological and functional changes that are ordinarily seen in the elderly in the general population. Stroke, silent cerebral infarcts, cardiomegaly, heart failure, pulmonary hypertension, nephropathy with proteinuria, osteopenia, osteoporosis, osteonecrosis, gout, and infections are exceedingly common in SCD. In this review, we have attempted to draw parallels between SCD and accelerated aging syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.